Latest Financial Impact News

Qube Holdings has sold its 202-hectare Beveridge property interest for $111 million, booking a substantial $100 million pre-tax profit in FY26. The move frees Qube from development costs while keeping future operational options open.

Carlton Investments Limited has announced an on-market buy-back of up to 115,000 ordinary shares, set to run throughout 2026. The move signals a strategic capital management effort without requiring shareholder approval.

Receivers and administrators have been appointed to 54 pharmacies within the Infinity Retail Pharmacy Group, catching Paragon Care off guard despite ongoing debt restructuring talks. The company pledges to support an orderly resolution to maximise creditor returns.

RAS Technology Holdings will not renew its Complete Racing Solution contract with Stake in 2026, shifting focus to expanding in regulated markets and Asia’s burgeoning racing sector.

APA Group has agreed to sell its 20% stake in the Allgas gas distribution network to Stonepeak affiliates, marking another step in its strategy to simplify operations and focus on core growth areas.

IDP Education has updated its revenue recognition policy to recognise Student Placement revenue at census date across all jurisdictions, leading to restated FY25 financials and reaffirmed FY26 guidance.

Netwealth Group Limited will compensate members affected by the First Guardian Master Fund collapse with $101 million, impacting its 1H26 profit but aiming to restore member confidence swiftly.

HITIQ Limited and Sportscover have forged an exclusive partnership to embed PROTEQT™, a cutting-edge concussion management system, into Sportscover’s sports insurance policies, starting with Hockey Australia and set to expand further.

Sequoia Financial Group reports a 15% rise in EBITDA year-to-date November 2025 despite legacy claim settlements and expected impairments, while its APAC expansion gains momentum.

Mt Malcolm Mines has executed a binding agreement to acquire key components of a 500,000 tonnes per annum gold processing plant, positioning itself for future self-processing and toll-milling opportunities in the prolific Leonora gold region.

Acrux Limited has sold the US registration and distribution rights for its Prilocaine 2.5% and Lidocaine 2.5% cream for US$550,000, redirecting resources towards its growing Hormone Replacement Therapy portfolio.

Locate Technologies Limited will be suspended from ASX trading following court approval of a scheme making Locate NZ the new parent company.